Eli Lilly and Company details up to 30 pound weight loss in obesity drug studies for menopause

Traders Union
All News
Companies
Eli Lilly slips 0.46% today

Highlights

Eli Lilly maintains a strong bullish trend, with price well above key short- and long-term technical supports.
The stock consolidates after reaching new all-time highs, with this week’s trading reflecting moderate volatility and stability.
Projected trading range for the coming week is $1,100 to $1,165, with signals strongly favoring further upside but some near-term overbought risks.

Bullish momentum persists as price holds above key moving averages

Eli Lilly’s price of $1,120.05 remains well above the MA-20 ($1,045.74), MA-50 ($972.74), and MA-200 ($947.52) on D1, confirming sustained bullish momentum across short, medium, and long-term trends. The Ichimoku Kijun sits at $1,031.42 and, being below the current price, acts as immediate support. Near-term support is clustered at the MA-20 ($1,045.74), with key support at the MA-50 ($972.74). Immediate resistance lies near the $1,166 area, just above the recent weekly high and above current price levels.

Upward momentum moderates amid overbought signals and weekly consolidation

Momentum signals on D1 (MACD and ADX) both indicate a persistent upward bias, though the ADX’s moderate level suggests the trend’s strength is not extreme. Overbought signals dominate from CCI and BBP, while RSI is elevated at 66.37 but not yet at critical extremes. Stoch RSI is neutral, with some conflicting overbought/oversold readings across intraday frames. BBP on D1 signals buyer dominance, though intraday BBP and Stoch RSI show momentary seller pushes. Eli Lilly has risen $16.59 (1.50%) over the week, trading at $1,120.05 up from the prev_week_close of $1,103.46. The price is currently in the middle of the weekly range, and weekly volatility stands at 10.82%. This week’s tone reflects moderate consolidation after a test of new all-time highs.

Upside favored with rangebound risk as multi-timeframe signals align

For the coming week, the projected trading range is $1,100 to $1,165, anchored near the middle of the 52-week span between $624.40 and $1,166.03. The probability of a price increase is very high (more than 80%), given unanimous “Buy” signals on RSI-W1, ADX-W1, MACD-W1, and MA-50-W1; the likelihood of a decline is thus very low. In the baseline scenario, the stock remains rangebound between support at $1,045–$1,100 and resistance around $1,165. A bullish breakout above $1,165 could target new highs, while a bearish move below $1,100 would expose the $1,045–$1,031 support zone. The prevailing trend and multi-timeframe momentum strongly favor upward bias, but overbought conditions warrant monitoring for any short-term pullbacks.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Eli Lilly maintained a bullish outlook supported by strong technical momentum and positive clinical developments. In light of recent market dynamics, investors should monitor for a decisive breakout or reversal as the prevailing scenario will hinge on whether current support levels continue to hold.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.